X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
QTX3046, a novel orally bioavailable, brain-penetrant, non-covalent allosteric KRASG12D inhibitor has announced dosing of first patient in Phase 1/1b trail for the treatment of advanced solid tumors.
Lead Product(s): QTX3046,Cetuximab
Therapeutic Area: Oncology Product Name: QTX3046
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Details:
QTX3034 is a G12D-preferring Multi-KRAS Inhibitor which is being evaluated for the treatment of patients with advanced KRASG12D-mutant solid tumors as monotherapy and in combination with cetuximab.
Lead Product(s): QTX3034
Therapeutic Area: Oncology Product Name: QTX3034
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
The proceeds from the financing will be used to advance Quanta’s pipeline including two chemically distinct allosteric KRAS inhibitors, QTX3034, a potent, selective, and orally bioavailable allosteric multi-KRAS inhibitor, and QTX3046, a G12D-selective KRAS inhibitor.
Lead Product(s): QTX3034
Therapeutic Area: Oncology Product Name: QTX3034
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avidity Partners
Deal Size: $50.7 million Upfront Cash: Undisclosed
Deal Type: Series D Financing May 22, 2023
Details:
QTX3034 is a potent, selective and orally bioavailable allosteric KRAS inhibitor which selectively targets protein-protein interactions that are key to oncogenic KRAS activity.
Lead Product(s): QTX3034
Therapeutic Area: Oncology Product Name: QTX3034
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
The Company will use proceeds from this financing round to advance programs targeting RAF1 and KRAS through clinical candidate selection, and IND filing, to reach initial proof-of-concept.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Surveyor Capital
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
